Emphysema - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Emphysema - Pipeline Review, H2 2016’, provides an overview of the Emphysema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Emphysema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Emphysema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Emphysema

The report reviews pipeline therapeutics for Emphysema by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Emphysema therapeutics and enlists all their major and minor projects

The report assesses Emphysema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Emphysema

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Emphysema

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Emphysema pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Angion Biomedica Corp.

ProMetic Life Sciences Inc.

rEVO Biologics, Inc.

SATT North SAS

TGV-Laboratories

Angion Biomedica Corp.

ProMetic Life Sciences Inc.

rEVO Biologics, Inc.

SATT North SAS

TGV-Laboratories

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Emphysema Overview ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Emphysema Overview 6

Therapeutics Development 7

Pipeline Products for Emphysema - Overview 7

Pipeline Products for Emphysema - Comparative Analysis 8

Emphysema - Therapeutics under Development by Companies 9

Emphysema - Therapeutics under Investigation by Universities/Institutes 10

Emphysema - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Emphysema - Products under Development by Companies 13

Emphysema - Products under Investigation by Universities/Institutes 14

Emphysema - Companies Involved in Therapeutics Development 15

Angion Biomedica Corp. 16

ProMetic Life Sciences Inc. 17

rEVO Biologics, Inc. 18

SATT North SAS 19

TGV-Laboratories 20

Emphysema - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

alpha-1 proteinase inhibitor (human) - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

alpha-1 proteinase inhibitor (human) - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Antibody for Emphysema - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

BB-3 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

EDO-66 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

MG-53 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Monoclonal Antibody to Inhibit EMAP II for Emphysema - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Mul-1867 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Peptide to Inhibit Beta Galactosidase for Pulmonary Emphysema - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Recombinant Human Alpha-1 Antitrypsin - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

TM-5441 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Emphysema - Dormant Projects 45

Emphysema - Discontinued Products 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Emphysema, H2 2016 7

Number of Products under Development for Emphysema - Comparative Analysis, H2 2016 8 ...

List of Tables

Number of Products under Development for Emphysema, H2 2016 7

Number of Products under Development for Emphysema - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Emphysema - Pipeline by Abeona Therapeutics, Inc. , H2 2016 15

Emphysema - Pipeline by Angion Biomedica Corp., H2 2016 16

Emphysema - Pipeline by ProMetic Life Sciences Inc., H2 2016 17

Emphysema - Pipeline by rEVO Biologics, Inc., H2 2016 18

Emphysema - Pipeline by SATT North SAS, H2 2016 19

Emphysema - Pipeline by TGV-Laboratories, H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Emphysema - Dormant Projects, H2 2016 45

Emphysema - Discontinued Products, H2 2016 46

List of Figures

List of Figures

Number of Products under Development for Emphysema, H2 2016 7

Number of Products under Development for Emphysema - Comparative Analysis, H2 2016 8 ...

List of Figures

Number of Products under Development for Emphysema, H2 2016 7

Number of Products under Development for Emphysema - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 22

Number of Products by Stage and Targets, H2 2016 22

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports